Varlilumab Biosimilar - Research Grade

Human

CD27

>1mg/ml

Human IgG4

Anti-Mouse CD27 (RM27-3E5) In Vivo Antibody - Low Endotoxin (ICH1185), Boserolimab Biosimilar - Research Grade (ICH5411)

https://www.imgt.org/mAb-DB/

ICH3002

P26842

939

RRID:AB_2921569

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-CD27 antibody varlilumab, produced for research use only. It is a fully recombinant human immunoglobulin engineered to recognise the same CD27 target as the originator molecule, built around the CD27 antigen rather than being the clinical drug itself; it is not intended for human or veterinary use. The analog is useful as a defined, reproducible reagent for target-engagement studies: it serves as a positive control in CD27 binding, staining and neutralisation-style assays, as a benchmarking tool when characterising other anti-CD27 reagents, and as a building block for antibody-engineering and effector-function work (for example ADCC or antibody-drug-conjugate development pipelines). It is supplied in formats suited to demanding preclinical and in-vitro experiments, including low-endotoxin research grade (<1 EU/mg) and ultra-low-endotoxin (<0.5 EU/mg) options, and is available in bulk milligram-to-gram quantities to support assay development, scale-up and repeat experiments. As a research-grade biosimilar it lets laboratories work with a consistent, well-defined anti-CD27 tool without sourcing clinical material. CD27 (TNFRSF7; UniProt P26842) is a type I transmembrane glycoprotein and a member of the tumour necrosis factor receptor superfamily. It is expressed on naive and memory T cells, subsets of B cells, and NK cells, functioning as a costimulatory receptor. Its sole known ligand is CD70 (CD27L), which is transiently expressed on activated lymphocytes and antigen-presenting cells. CD27-CD70 engagement, in concert with T-cell receptor signalling, promotes T-cell activation, clonal expansion, survival and the generation and maintenance of memory and effector populations, and contributes to NK-cell and B-cell responses. Signalling proceeds through TRAF proteins to NF-kappaB and JNK pathways. Because it amplifies adaptive immunity, CD27 is an important costimulatory node studied in tumour immunology, vaccine and immunotherapy contexts. A soluble form of CD27 can be shed and is sometimes used as an activation marker.

CDX-1127

Detects human CD27. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Varlilumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Varlilumab (anti-CD27) Biosimilar

Q: Is the Varlilumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Varlilumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Varlilumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Varlilumab that binds human CD27.